Given the number of risk factors, uncertainties and assumptions discussed below, actual results may differ materially. The foregoing forward‐looking statements reflect our expectations as of today's date. We are confident we have the right Board and management team in place to guide TRHC forward and drive sustainable value for our stockholders as the Company continues to execute on its strategy." Tunstall continued, "We have an accomplished, diverse, and highly engaged Board with deep, relevant industry experience and business acumen, including nine directors who bring proven expertise across healthcare, finance, public service, and academia. In that spirit, the Board and management team have spoken with Indaba on multiple occasions since their initial investment in the Company in April 2022 to understand their point of view, and we expect to continue our dialogue with them and other stockholders as part of our normal investor relations process." Gordon Tunstall, TRHC's Lead Independent Director, commented on the public statements made by Indaba: "TRHC's Board of Directors and management team always strive to maintain an active dialogue with stockholders and welcome input and ideas on ways to create value and to continue to enhance our corporate governance. We continue to make important progress on both fronts as we recalibrate the business for the significant opportunities ahead in the PACE market."
We also are pleased with our team's efforts to unlock value by pursuing opportunities to divest non-core assets as we sharpen our strategic focus and strengthen our balance sheet. Knowlton, PhD, TRHC's Chief Executive Officer, Chairman and Founder, said, "Our preliminary second quarter revenue performance underscores the ongoing momentum in the business as we continue to see increased demand for our core offering.
#Tabula rasa healthcare stock price full
The Company intends to report full unaudited financial results for the second quarter of 2022 in early August.Ĭommenting on the preliminary results, Calvin H. Preliminary unaudited revenue from continuing operations for the second quarter of 2022 is expected to be between $72 – $73 million, exceeding the prior guidance range of $66 – $69 million. ("TRHC" or the "Company") (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medications, today reported preliminary unaudited financial results for the second quarter ended Jand commented on public statements made today by Indaba Capital Management, L.P. MOORESTOWN, N.J., J/PRNewswire/ - Tabula Rasa HealthCare, Inc. Company Comments on Public Statements by Indaba Capital Management.Reports Preliminary Revenue from Continuing Operations of $72 to $73 Million for the Second Quarter of 2022, Exceeding Prior Guidance Range and Continuing Strong 2022 Performance as Company Focuses on Core Business.was founded in 2009 and is headquartered in Moorestown, New Jersey.
#Tabula rasa healthcare stock price software
The company provides cloud-based software applications to assist prescribers and pharmacists. As of December 31, 2021, it served approximately 150 healthcare organizations and 350 health plans and approximately 18,000 retail pharmacies. Further, the company provides clinical pharmacist collaboration, prescription fulfillment and adherence packaging, and pharmacy benefit management services, as well as health plan management services, including risk adjustment and third party administrator services. In addition, it offers DoseMeRx, a decision support software that leverages clinically validated pharmacokinetic drug models, patient characteristics, drug concentrations, and genotypes to guide dose optimization and PrescribeWellness, a PrescribeWellness, a patient engagement center platform. The company also provides TruChart that offers electronic health records (EHR), care coordination, and financial management in one program allowing Programs of All-Inclusive Care for the Elderly (PACE) to track measurable outcomes in defined timeframes for the populations they serve and PACElogic, which delivers sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state that requires reporting. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. operates as a healthcare technology company in the United States.
0 kommentar(er)
